Gossamer Bio Receives Nasdaq Notice Regarding Minimum Bid Price Deficiency
On April 8, 2026, Gossamer Bio, Inc. received a formal notice from the Nasdaq Stock Market indicating that the company is no longer in compliance with the Minimum Bid Price Requirement set forth in Nasdaq Listing Rule 5450(a)(1). The notice was triggered because the closing bid price of the companyβs common stock remained below $1.00 per share for 30 consecutive business days, specifically from February 24, 2026, to April 7, 2026. This notification does not result in an immediate delisting. Under Nasdaq Listing Rule 5810(c)(3)(A), Gossamer Bio has a compliance period of 180 calendar days, ending on October 5, 2026, to regain compliance. To achieve this, the stock's closing bid price must be at least $1.00 for a minimum of ten consecutive business days. If compliance is not met by the deadline, the company may be eligible for an additional 180-day grace period, provided it meets other listing requirements and potentially implements measures such as a reverse stock split. The company stated it intends to monitor the situation and evaluate options to address the deficiency.